엔지켐생명과학

183490KOSDAQ기초 의약물질 제조업

61.3 / 100

Reference Date: 2026-06-10

Financial Score23.0 / 40

News Sentiment21.3 / 25

Momentum5.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Enzychem Life Sciences focuses on global new drug development, API manufacturing, health functional foods, and bio-oil production. The company is advancing the development of EC-18, a treatment for chemotherapy-induced oral mucositis, and expanding into AI-driven drug discovery and DAC technology. Its API division exports over 40 products globally, while its health functional food segment offers immune-supporting products like 'LockFeed Immune'.

Number of Employees

116people

Average Salary

48.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

0.60Industry Average 1.747.0Point

Half of industry avg (excellent)

ROE

-12.05Industry Average -6.033.5Point

2.0x industry avg (good)

Debt Ratio

1.15Industry Average 6.628.0Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼5.3% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼0.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -9.7% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
엔지켐, '대장암' 정밀 저격한 차세대 항암 기술 개발
엔지켐생명과학이 혁신적인 차세대 항암 기술 개발로 글로벌 시장 진출 가능성을 높여 긍정적인 시장 반응을 기대.
Positive
엔지켐생명과학, 타깃링크와 차세대 DAC 항암 플랫폼 개발 추진
엔지켐생명과학이 타깃링크테라퓨틱스와 협력하여 혁신적인 DAC 항암 플랫폼 개발로 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 990Won52-week high 1,69952-week low 968

1-month return3.0Point

1m 0% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 1Neutral 5Negative 0

Neutral[기재정정]주식등의대량보유상황보고서(일반)2026-06-05
Neutral[기재정정]주식등의대량보유상황보고서(일반)2026-06-05
Neutral주식등의대량보유상황보고서(일반)2026-06-01
Neutral주식등의대량보유상황보고서(일반)2026-05-28
Positive[기재정정]주요사항보고서(자기주식취득신탁계약체결결정)2026-05-26